Innovent and HutchMed Report Positive Results from Combo CRC Therapy

Suzhou Innovent Bio and HutchMed announced positive data from their combination therapy for colorectal cancer. The regimen combines Innovent's approved PD-1, Tyvyt® (sintilimab injection) with HutchMed's VEGFR inhibitor, Elunate® (fruquintinib), as a third-line therapy for CRC. In 44 previously treated CRC patients, the objective response rate was 22.7%, about double the ORR of Elunate alone. The Phase Ib trial tested safety and efficacy of the combination and determined the recommended Phase II dose. More details... Stock Symbols: (HK: 01801) (NSDQ/AIM: HCM) Share this with colleagues: // //